Health Secretary Robert F. Kennedy Jr.’s new vaccine advisor stirred some uncertainty regarding Covid-19 vaccinations this fall.
Up to now, nearly every American who wanted a Covid-19 vaccine has had access to it on a daily basis. However, the Food and Drug Administration recently introduced new restrictions for this year’s vaccines from Pfizer, Moderna, and Novavax. These shots are now intended primarily for those under 65 who are at elevated risk.
During a series of votes, advisors at the Centers for Disease Control and Prevention stopped short of recommending vaccines but emphasized that individuals should make personal choices.
The panel also urged the CDC to use stronger language regarding the anticipated risks associated with vaccination, a proposal that faced pushback from an outside medical group citing a solid safety record for the vaccines.
Interestingly, the divided panel nearly suggested that a prescription should be required for vaccines.
Dr. Sean O’Leary from the American Academy of Pediatrics described the decision not to recommend vaccinations as “very vague,” pointing out that it could have significant repercussions for American children.
He noted that the discussion seems to reflect a growing “distrust” surrounding vaccines.
“It was a very strange meeting,” O’Leary remarked.
Although the Covid-19 vaccine still isn’t complete, data from the CDC indicates it offers the best protection against severe illness and death, even for those who might still contract the virus. With the virus naturally evolving, reinfections can happen.
Similar to flu shots, Covid-19 vaccines are updated every year. However, only around 44% of seniors and 13% of children received the latest vaccinations last year, according to the CDC.
“I don’t think it’s wise for people to give recommendations that they don’t then adhere to,” Dr. Cody Meissner, a panelist from Dartmouth University, said.
Another aspect under consideration involves a rare side effect linked to the vaccine in young men—myocarditis, a form of heart inflammation. Researchers attempting to explore whether certain genetic predispositions heighten risk mentioned that the Trump administration had cut funding for their study before it was completed.
The panel’s focus on Covid-19 vaccinations comes as the virus remains a public health concern. CDC reports from June noted that the virus resulted in between 32,000 and 51,000 deaths in the U.S., along with over 250,000 hospitalizations last fall and winter, with the most significant risks falling on the elderly and unvaccinated young children.
Concerns about access have prompted major healthcare organizations, including the American Academy of Pediatrics, to recommend that vaccines remain available to individuals over six months of age, including pregnant women, as was previously done.
In response to ACIP’s decisions, some states have begun implementing policies to ensure vaccine access. Meanwhile, the organization representing the majority of health insurance providers, America’s Health Insurance Plans, affirmed that its members will continue to cover the vaccinations until 2026.
The panel opened the second day of its meeting with ongoing confusion over whether to terminate the long-standing CDC recommendation for, well, newborns to receive vaccinations against hepatitis B at birth.
They were also debating whether to suggest delaying this initial vaccination, a consideration doctors and parents can already make independently. Nonetheless, following criticism from pediatric and infectious disease specialists for potentially undermining vaccine safety, the advisors decided to table the matter for now.
On the previous day, the panel had recommended new restrictions regarding another childhood vaccine.
For children under four, they advised that the initial protective doses for measles, mumps, and rubella (MMR) should be administered as separate injections rather than the combined MMRV version. Since 2009, the CDC has favored individual shots for early vaccination, which is already the preference for 85% of infants.
On Friday, the committee also advised that the government’s childhood vaccination program—responsible for covering costs for around half of U.S. children—coordinate its limited use of MMRV and its guidelines.
